Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.

Zeuzem S, Bourgeois S, Greenbloom S, Buti M, Aghemo A, Lampertico P, Janczewska E, Lim SG, Moreno C, Buggisch P, Tam E, Corbett C, Willems W, Vijgen L, Fevery B, Ouwerkerk-Mahadevan S, Ackaert O, Beumont M, Kalmeijer R, Sinha R, Biermer M; OMEGA-1 study team.

Hepatology. 2019 Jun;69(6):2349-2363. doi: 10.1002/hep.30527. Epub 2019 Mar 14.

PMID:
30693573
2.

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.

McClure MW, Berliba E, Tsertsvadze T, Streinu-Cercel A, Vijgen L, Astruc B, Patat A, Westland C, Chanda S, Zhang Q, Kakuda TN, Vuong J, Khorlin N, Beigelman L, Blatt LM, Fry J.

PLoS One. 2018 Oct 16;13(10):e0204974. doi: 10.1371/journal.pone.0204974. eCollection 2018.

3.

Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.

Gane EJ, Stedman CA, Schwabe C, Vijgen L, Chanda S, Kakuda TN, Fry J, Blatt LM, McClure MW.

Hepatology. 2018 Dec;68(6):2145-2157. doi: 10.1002/hep.30126. Epub 2018 Nov 19.

PMID:
30070722
4.

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.

Sulkowski MS, Feld JJ, Lawitz E, Felizarta F, Corregidor AM, Khalid O, Ghalib R, Smith WB, Van Eygen V, Luo D, Vijgen L, Gamil M, Kakuda TN, Ouwerkerk-Mahadevan S, Van Remoortere P, Beumont M.

J Viral Hepat. 2018 Jun;25(6):631-639. doi: 10.1111/jvh.12853. Epub 2018 Feb 6.

PMID:
29274193
5.

Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.

Bourgeois S, Horsmans Y, Nevens F, van Vlierberghe H, Moreno C, Beumont M, Vijgen L, van Eygen V, Luo D, Hillewaert V, Van Remoortere P, van de Logt J, Ouwerkerk-Mahadevan S.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01217-17. doi: 10.1128/AAC.01217-17. Print 2017 Dec.

6.

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.

Vijgen L, Thys K, Vandebosch A, Van Remoortere P, Verloes R, De Meyer S.

Virol J. 2017 May 31;14(1):101. doi: 10.1186/s12985-017-0760-2.

7.

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.

Bourgeois S, Van Vlierberghe H, Moreno C, Orlent H, Nevens F, Arastéh K, Horsmans Y, Schattenberg JM, Buggisch P, Francque S, Vijgen L, Kakuda TN, Hoeben E, Luo D, Vandebosch A, Jacquemyn B, Van Remoortere P, Verloes R.

BMC Gastroenterol. 2017 Feb 10;17(1):26. doi: 10.1186/s12876-017-0580-2.

8.

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.

Lawitz E, Poordad F, Gutierrez JA, Kakuda TN, Picchio G, Beets G, Vandevoorde A, Van Remoortere P, Jacquemyn B, Luo D, Ouwerkerk-Mahadevan S, Vijgen L, Van Eygen V, Beumont M.

J Viral Hepat. 2017 Apr;24(4):287-294. doi: 10.1111/jvh.12645. Epub 2016 Nov 23.

PMID:
27878906
9.

Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosphate Useful for HCV Inhibition.

Jonckers TH, Tahri A, Vijgen L, Berke JM, Lachau-Durand S, Stoops B, Snoeys J, Leclercq L, Tambuyzer L, Lin TI, Simmen K, Raboisson P.

J Med Chem. 2016 Jun 23;59(12):5790-8. doi: 10.1021/acs.jmedchem.6b00382. Epub 2016 Jun 3.

PMID:
27181575
10.

In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.

Verbinnen T, Fevery B, Vijgen L, Jacobs T, De Meyer S, Lenz O.

Antimicrob Agents Chemother. 2015 Dec;59(12):7548-57. doi: 10.1128/AAC.01444-15. Epub 2015 Sep 21.

11.

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, Buelens A, Ceulemans H, Beumont M, Picchio G, De Meyer S.

J Hepatol. 2015 May;62(5):1008-14. doi: 10.1016/j.jhep.2014.11.032. Epub 2014 Nov 28.

12.

Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase.

Jonckers TH, Vandyck K, Vandekerckhove L, Hu L, Tahri A, Van Hoof S, Lin TI, Vijgen L, Berke JM, Lachau-Durand S, Stoops B, Leclercq L, Fanning G, Samuelsson B, Nilsson M, Rosenquist Å, Simmen K, Raboisson P.

J Med Chem. 2014 Mar 13;57(5):1836-44. doi: 10.1021/jm4015422. Epub 2014 Jan 6.

PMID:
24345201
13.

Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.

Cummings MD, Lin TI, Hu L, Tahri A, McGowan D, Amssoms K, Last S, Devogelaere B, Rouan MC, Vijgen L, Berke JM, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Fanning G, Nyanguile O, Simmen K, Van Remoortere P, Raboisson P, Vendeville S.

J Med Chem. 2014 Mar 13;57(5):1880-92. doi: 10.1021/jm401396p. Epub 2013 Nov 8.

PMID:
24144360
14.

A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.

Vijgen L, Verbeeck J, Van Kerckhove B, Berke JM, Koletzki D, Fanning G, Lenz O.

Methods Mol Biol. 2013;1030:105-17. doi: 10.1007/978-1-62703-484-5_9.

PMID:
23821263
15.

Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).

Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, De Smedt G, Moreno C, Picchio G.

J Hepatol. 2013 Mar;58(3):445-51. doi: 10.1016/j.jhep.2012.10.028. Epub 2012 Nov 7.

PMID:
23142061
16.

Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy.

Lenz O, de Bruijne J, Vijgen L, Verbinnen T, Weegink C, Van Marck H, Vandenbroucke I, Peeters M, Simmen K, Fanning G, Verloes R, Picchio G, Reesink H.

Gastroenterology. 2012 Nov;143(5):1176-1178.e6. doi: 10.1053/j.gastro.2012.07.117. Epub 2012 Aug 8.

PMID:
22885330
17.

Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.

Verbinnen T, Jacobs T, Vijgen L, Ceulemans H, Neyts J, Fanning G, Lenz O.

J Antimicrob Chemother. 2012 Oct;67(10):2327-37. doi: 10.1093/jac/dks234. Epub 2012 Jun 21.

PMID:
22723600
18.

TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.

Devogelaere B, Berke JM, Vijgen L, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Nyanguile O, Tahri A, Amssoms K, Lenz O, Cummings MD, Clayton RF, Vendeville S, Raboisson P, Simmen KA, Fanning GC, Lin TI.

Antimicrob Agents Chemother. 2012 Sep;56(9):4676-84. doi: 10.1128/AAC.00245-12. Epub 2012 Jun 18.

19.

Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055.

Vendeville S, Lin TI, Hu L, Tahri A, McGowan D, Cummings MD, Amssoms K, Canard M, Last S, Van den Steen I, Devogelaere B, Rouan MC, Vijgen L, Berke JM, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Fanning G, Van Emelen K, Nyanguile O, Simmen K, Raboisson P.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4437-43. doi: 10.1016/j.bmcl.2012.04.113. Epub 2012 Apr 30.

PMID:
22633687
20.

Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series.

McGowan D, Vendeville S, Lin TI, Tahri A, Hu L, Cummings MD, Amssoms K, Berke JM, Canard M, Cleiren E, Dehertogh P, Last S, Fransen E, Van Der Helm E, Van den Steen I, Vijgen L, Rouan MC, Fanning G, Nyanguile O, Van Emelen K, Simmen K, Raboisson P.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4431-6. doi: 10.1016/j.bmcl.2012.03.097. Epub 2012 Apr 3.

PMID:
22542193
21.

Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties.

Cummings MD, Lin TI, Hu L, Tahri A, McGowan D, Amssoms K, Last S, Devogelaere B, Rouan MC, Vijgen L, Berke JM, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Fanning G, Van Emelen K, Nyanguile O, Simmen K, Raboisson P, Vendeville S.

Angew Chem Int Ed Engl. 2012 May 7;51(19):4637-40. doi: 10.1002/anie.201200110. Epub 2012 Mar 30. No abstract available.

PMID:
22473861
22.

Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.

Berke JM, Vijgen L, Lachau-Durand S, Powdrill MH, Rawe S, Sjuvarsson E, Eriksson S, Götte M, Fransen E, Dehertogh P, Van den Eynde C, Leclercq L, Jonckers TH, Raboisson P, Nilsson M, Samuelsson B, Rosenquist Å, Fanning GC, Lin TI.

Antimicrob Agents Chemother. 2011 Aug;55(8):3812-20. doi: 10.1128/AAC.00214-11. Epub 2011 May 16.

23.

2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase.

Jonckers TH, Lin TI, Buyck C, Lachau-Durand S, Vandyck K, Van Hoof S, Vandekerckhove LA, Hu L, Berke JM, Vijgen L, Dillen LL, Cummings MD, de Kock H, Nilsson M, Sund C, Rydegård C, Samuelsson B, Rosenquist A, Fanning G, Van Emelen K, Simmen K, Raboisson P.

J Med Chem. 2010 Nov 25;53(22):8150-60. doi: 10.1021/jm101050a. Epub 2010 Oct 29.

PMID:
21033671
24.

Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.

Verbinnen T, Van Marck H, Vandenbroucke I, Vijgen L, Claes M, Lin TI, Simmen K, Neyts J, Fanning G, Lenz O.

J Virol. 2010 Nov;84(21):11124-33. doi: 10.1128/JVI.01217-10. Epub 2010 Aug 25.

25.

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA.

Antimicrob Agents Chemother. 2010 May;54(5):1878-87. doi: 10.1128/AAC.01452-09. Epub 2010 Feb 22.

26.

1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.

Nyanguile O, Devogelaere B, Vijgen L, Van den Broeck W, Pauwels F, Cummings MD, De Bondt HL, Vos AM, Berke JM, Lenz O, Vandercruyssen G, Vermeiren K, Mostmans W, Dehertogh P, Delouvroy F, Vendeville S, VanDyck K, Dockx K, Cleiren E, Raboisson P, Simmen KA, Fanning GC.

J Virol. 2010 Mar;84(6):2923-34. doi: 10.1128/JVI.01980-09. Epub 2010 Jan 13.

27.

Development of a real-time multiplex RSV detection assay for difficult respiratory samples, using ultrasone waves and MNAzyme technology.

Nauwelaers D, Vijgen L, Atkinson C, Todd A, Geretti AM, Van Ranst M, Stuyver L.

J Clin Virol. 2009 Nov;46(3):238-43. doi: 10.1016/j.jcv.2009.08.013. Epub 2009 Sep 15.

PMID:
19758841
28.

Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.

Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P.

Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21. doi: 10.1128/AAC.01509-08. Epub 2009 Jun 8.

29.

A pancoronavirus RT-PCR assay for detection of all known coronaviruses.

Vijgen L, Moës E, Keyaerts E, Li S, Van Ranst M.

Methods Mol Biol. 2008;454:3-12. doi: 10.1007/978-1-59745-181-9_1.

PMID:
19057882
30.

In Vitro Antiviral Activity of some Novel Isatin Derivatives against HCV and SARS-CoV Viruses.

Selvam P, Murgesh N, Chandramohan M, De Clercq E, Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst MV.

Indian J Pharm Sci. 2008 Jan;70(1):91-4. doi: 10.4103/0250-474X.40339.

31.

Subgroup prevalence and genotype circulation patterns of human respiratory syncytial virus in Belgium during ten successive epidemic seasons.

Zlateva KT, Vijgen L, Dekeersmaeker N, Naranjo C, Van Ranst M.

J Clin Microbiol. 2007 Sep;45(9):3022-30. Epub 2007 Jul 3.

32.

Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle.

Keyaerts E, Vijgen L, Pannecouque C, Van Damme E, Peumans W, Egberink H, Balzarini J, Van Ranst M.

Antiviral Res. 2007 Sep;75(3):179-87. Epub 2007 Mar 30.

PMID:
17428553
33.

Evolutionary history of the closely related group 2 coronaviruses: porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, and human coronavirus OC43.

Vijgen L, Keyaerts E, Lemey P, Maes P, Van Reeth K, Nauwynck H, Pensaert M, Van Ranst M.

J Virol. 2006 Jul;80(14):7270-4.

34.

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.

Balzarini J, Keyaerts E, Vijgen L, Egberink H, De Clercq E, Van Ranst M, Printsevskaya SS, Olsufyeva EN, Solovieva SE, Preobrazhenskaya MN.

Antiviral Res. 2006 Oct;72(1):20-33. Epub 2006 Apr 6.

PMID:
16675038
35.

Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture.

Balzarini J, Keyaerts E, Vijgen L, Vandermeer F, Stevens M, De Clercq E, Egberink H, Van Ranst M.

J Antimicrob Chemother. 2006 Mar;57(3):472-81. Epub 2005 Dec 30.

PMID:
16387746
36.
37.

Viral load quantitation of SARS-coronavirus RNA using a one-step real-time RT-PCR.

Keyaerts E, Vijgen L, Maes P, Duson G, Neyts J, Van Ranst M.

Int J Infect Dis. 2006 Jan;10(1):32-7. Epub 2005 Jul 14.

38.

Circulation of genetically distinct contemporary human coronavirus OC43 strains.

Vijgen L, Keyaerts E, Lemey P, Moës E, Li S, Vandamme AM, Van Ranst M.

Virology. 2005 Jun 20;337(1):85-92.

39.

Growth kinetics of SARS-coronavirus in Vero E6 cells.

Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M.

Biochem Biophys Res Commun. 2005 Apr 15;329(3):1147-51.

PMID:
15752773
40.

Genetic variability of human respiratory coronavirus OC43.

Vijgen L, Lemey P, Keyaerts E, Van Ranst M.

J Virol. 2005 Mar;79(5):3223-4; author reply 3224-5. No abstract available.

41.

A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium.

Moës E, Vijgen L, Keyaerts E, Zlateva K, Li S, Maes P, Pyrc K, Berkhout B, van der Hoek L, Van Ranst M.

BMC Infect Dis. 2005 Feb 1;5:6.

42.

Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event.

Vijgen L, Keyaerts E, Moës E, Thoelen I, Wollants E, Lemey P, Vandamme AM, Van Ranst M.

J Virol. 2005 Feb;79(3):1595-604.

43.

Poliovirus sampling by using sodium dodecyl sulfate/EDTA-pretreated chromatography paper strips.

Maes P, Van Doren E, Denys B, Thoelen I, Rahman M, Vijgen L, Van Ranst M.

Biochem Biophys Res Commun. 2004 Dec 17;325(3):711-5.

PMID:
15541347
44.

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine.

Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M.

Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8.

PMID:
15351731
45.

Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound.

Keyaerts E, Vijgen L, Chen L, Maes P, Hedenstierna G, Van Ranst M.

Int J Infect Dis. 2004 Jul;8(4):223-6.

46.

Identification of six new polymorphisms in the human coronavirus 229E receptor gene (aminopeptidase N/CD13).

Vijgen L, Keyaerts E, Zlateva K, Van Ranst M.

Int J Infect Dis. 2004 Jul;8(4):217-22.

47.

Absence of the Kilifi mutation in the rhinovirus-binding domain of ICAM-1 in a Caucasian population.

Vijgen L, Van Essche M, Van Ranst M.

Genet Test. 2003 Summer;7(2):159-61.

PMID:
12885341
48.

Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease.

Vijgen L, Van Gysel M, Rector A, Thoelen I, Esters N, Ceelen T, Vangoidsenhoven E, Vermeire S, Rutgeerts P, Van Ranst M.

Genes Immun. 2002 Nov;3(7):400-6.

Supplemental Content

Loading ...
Support Center